Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.51 |
| ▸ | LPL | P06858 | 12/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23484478 | 0.84 | MAPK1 (0.50) | MAPK1LIPGLPLHTR1D | |
| SCHEMBL30748763 | 0.78 | MAPK1 (0.53) | MAPK1LIPGLPLP2RX7 | |
| SCHEMBL24269979 | 0.78 | MAPK1 (0.53) | MAPK1LIPGLPLP2RX7 | |
| SCHEMBL22448147 | 0.78 | LIPG (0.54) | MAPK1LIPGLPLCA1CA2 | |
| SCHEMBL17548209 | 0.77 | MAPK1 (0.46) | MAPK1HTR1D | |
| SCHEMBL17547940 | 0.77 | MAPK1 (0.51) | MAPK1LIPGLPLP2RX7HTR1D | |
| SCHEMBL24681148 | 0.76 | MAPK1 (0.45) | MAPK1HTR1D | |
| SCHEMBL29914408 | 0.76 | MAPK1 (0.45) | MAPK1HTR1D | |
| SCHEMBL12845155 | 0.76 | LIPG (0.53) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL24681571 | 0.76 | MAPK1 (0.44) | MAPK1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3712147-B1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SHANGDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10822365-B1 | SGLTS inhibitor and application thereof | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20200331950-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-10-22 | — | — | US | disclosed |
| EP-3712147-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | Shangdong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822365-B1 | SGLTS inhibitor and application thereof | SLC5A1, SLC5A2, SLC5A11 | MAPK1 769/4885LIPG 731/4885LPL 1016/4885 |
| US-20200331950-A1 | SGLTS INHIBITOR AND APPLICATION THEREOF | SLC5A1, SLC5A2, SLC5A11 | MAPK1 769/4885LIPG 731/4885LPL 1016/4885 |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | MAPK1 32/4885LIPG 3581/4885LPL 3297/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | MAPK1 2203/4885LIPG 485/4885LPL 658/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MAPK1 2203/4885LIPG 485/4885LPL 658/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | MAPK1 32/4885LIPG 3581/4885LPL 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.